BENNETT C FRANK

EVP, Chief Scientific Officer Bennett C Frank sold 85,089 shares at avg $79.23, reducing holdings by 51.4% on 2026-03-03

Bennett C Frank, EVP and Chief Scientific Officer, executed 3 separate sales on 2026-03-03 totaling 85,089 shares for $6,741,669.17 at prices ranging from $79.10 to $80.76, reducing his holdings from 165,643 shares to 80,554 shares—a 51.4% reduction in position size. The sales occurred near the company's 52-week high ($86.50), with the stock now trading at $75.16 and down 11.2% over 30 days and 8.0% over 90 days. At same-ticker IONS, his prior 5 trades show a 0% well-timed rate at the 90-day mark; his most recent prior sells on 2026-02-02 have posted -4.3% and -3.8% 30-day returns, while his September 2025 sells preceded gains (+34.1% and +66.8% respectively). The company is unprofitable (net income -$128.6M on quarterly revenue of $156.7M), though FY revenue grew 33.8%, creating a mixed fundamental backdrop for a substantial stake reduction by a senior scientist executive.

Chief Scientific Officer Bennett Frank sold 85.1K shares ($7.1M) at $82.93 blended avg; stock now $84.99

Bennett Frank, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, executed 3 separate sales totaling 85,089 shares for $7,056,215.53 on 2026-02-02, reducing his holdings by -51.4% from 165,382 to 80,293 shares. The sales occurred at a blended average price of $82.93, slightly below the current price of $84.99, suggesting a marginal near-term underperformance. Frank's prior sales at Ionis showed mixed timing: 3 of 5 prior sells were well-timed at the 90-day mark, with recent 2025 sales delivering notably strong 90-day returns (+34.1% and +66.8%), indicating these prior exits preceded subsequent price rallies rather than declines. The company operates unprofitably (net income $-128,606,000.00 over the most recent full fiscal year) amid annual revenue headwinds (-10.5%), which provide context for significant insider liquidation by a senior scientific executive.

EVP/CSO Bennett C Frank sold 38.9K shares at blended $59.14 after 68.2% 90-day rally.

Bennett C Frank, EVP and Chief Scientific Officer, executed 2 separate sales totaling 38,909 shares for $2,301,263.58, reducing his holdings by 30.5% from 127,588 to 88,679 shares. The sales came after a pronounced rally: IONS gained 68.2% over the prior 90 days and 37.9% over the prior 30 days, with the blended sale price of $59.14 placing the executive's exit near the 52-week high of $60.49. His prior sales at IONS show a consistent pattern: 4 of 4 prior trades were well-timed at the 90-day mark (all posted negative 90-day returns, ranging from -12.3% to -15.1%), suggesting a track record of exiting before declines. However, the company's fundamentals are mixed: while the latest quarter posted $123.6M net income, full-year net income was negative and annual revenue declined 10.5%, creating uncertainty around sustainability of recent gains.